5
Shared Docs
5
Same-Page
5 / 5
Mentions
itled to enforce any rights against the Underlying Fund or the Glendower GP or any of their affiliates, assert claims against the Underlying Fund, Glendower or their affiliates or have any voting rights in the Underlying Fund. An investor in the Access Fund will have only those rights provided for in th
nd SOF III as of September 30, 2017 and should be read and reviewed in conjunction and should be read and reviewed in conjunction with Appendix 5: Important Performance Information which sets forth, amongst other things, important information regarding the performance described above. Confidential Private Placement Memorandum
itled to enforce any rights against the Underlying Fund or the Glendower GP or any of their affiliates, assert claims against the Underlying Fund, Glendower or their affiliates or have any voting rights in the Underlying Fund. An investor in the Access Fund will have only those rights provided for in th
nd SOF III as of September 30, 2017 and should be read and reviewed in conjunction and should be read and reviewed in conjunction with Appendix 5: Important Performance Information which sets forth, amongst other things, important information regarding the performance described above. Confidential Private Placement Memorandum
itled to enforce any rights against the Underlying Fund or the Glendower GP or any of their affiliates, assert claims against the Underlying Fund, Glendower or their affiliates or have any voting rights in the Underlying Fund. An investor in the Access Fund will have only those rights provided for in th
nd SOF III as of September 30, 2017 and should be read and reviewed in conjunction and should be read and reviewed in conjunction with Appendix 5: Important Performance Information which sets forth, amongst other things, important information regarding the performance described above. Confidential Private Placement Memorandum
itled to enforce any rights against the Underlying Fund or the Glendower GP or any of their affiliates, assert claims against the Underlying Fund, Glendower or their affiliates or have any voting rights in the Underlying Fund. An investor in the Access Fund will have only those rights provided for in th
nd SOF III as of September 30, 2017 and should be read and reviewed in conjunction and should be read and reviewed in conjunction with Appendix 5: Important Performance Information which sets forth, amongst other things, important information regarding the performance described above. Confidential Private Placement Memorandum
itled to enforce any rights against the Underlying Fund or the Glendower GP or any of their affiliates, assert claims against the Underlying Fund, Glendower or their affiliates or have any voting rights in the Underlying Fund. An investor in the Access Fund will have only those rights provided for in th
nd SOF III as of September 30, 2017 and should be read and reviewed in conjunction and should be read and reviewed in conjunction with Appendix 5: Important Performance Information which sets forth, amongst other things, important information regarding the performance described above. Confidential Private Placement Memorandum
Entities connected to both Glendower and Important Performance Information
Glendower Capital
ORGANIZATIONAccess Fund
ORGANIZATION
Prince Charles
PERSON
Deutsche Bank
ORGANIZATIONSOF IV
ORGANIZATION
Credit Suisse
ORGANIZATIONCharles Smith
PERSONDeirdre Davies
PERSONAdam Graev
PERSON
United States
LOCATION
J. Robert Oppenheimer
PERSON
North America
LOCATIONGlobal Corporate Finance
ORGANIZATION
General Electric
ORGANIZATIONChi Cheung
PERSONDeirdre
PERSONColumbia Business School
ORGANIZATION
United Kingdom
LOCATION
Milan
LOCATIONPhilippe VAN DEN BROEK
PERSON